NEKTAR THERAPEUTICS
Customers
3
2 active
Suppliers
0
None disclosed
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Latest period
Dec 31, 2025
10-K filed 2026-03-13
Customers 3
Companies NKTR discloses as major customers, as a share of NKTR revenue. 2 active, 1 lapsed.
| Company | % of NKTR revenue | Est. revenue | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| PFE PFIZER INC |
12% | $11.8M | FY 2024-12-31 | Lapsed Last seen 2024-12-31 |
10-K 2026-03-13 | |
Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39%, 18%, 17%, 12% and 10% of our revenue, respectively, for the year ended December 31, 2024.Revenue by geographic area is based on the headquarters or shipping locations of our partners. | ||||||
| AZN ASTRAZENECA PLC |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-13 |
Revenue from Baxalta (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, and UCB represented 45%, 37%, and 14% of our revenue, respectively, for the year ended December 31, 2025. Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39%, 18%, 17%, 12% and 10% of our revenue, respectively, for the year ended December 31, 2024. | ||||||
| TAK TAKEDA PHARMACEUTICAL CO LTD |
Named | — | FY 2025-12-31 | — | Active | 10-K 2026-03-13 |
Revenue from Baxalta (a subsidiary of Takeda Pharmaceutical Company Limited), AstraZeneca, and UCB represented 45%, 37%, and 14% of our revenue, respectively, for the year ended December 31, 2025. | ||||||
Alerts are coming
Get an email when NKTR's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.